Press release
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2023, October 6-9, 2023. Data from an interim analysis of the ongoing open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of ATTR amyloidosis through 24 months will be presented. In addition, findings from a post-hoc analysis of the APOLLO-B Phase 3 study that further characterize the impact of patisiran on health status and quality of life in patients with the cardiomyopathy of ATTR amyloidosis will be presented, as well as demographics, baseline characteristics and safety data for patients who enrolled in the expanded access program (EAP) for patisiran.\n\n\nHFSA Presentation Details\n\n\n\nBaseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program\nPoster 087: General ePoster Viewing Session 1\nFriday, October 6, 2023, 7:00 – 7:30 p.m. ET\nPresenting Author: Naveen Saha\n\n\n\n\nPrimary Results from APOLLO-B Open-label Extension Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis\nPoster 021: Oral Abstract Session 4\nSaturday, October 7, 2023, 5:21 – 5:31 p.m. ET\nPresenting Author: Mathew Maurer\n\n\n\n\nImpact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis\nPoster 030: Oral Abstract Session 6\nSunday, October 8, 2023, 8:24 – 8:34 a.m. ET\nPresenting Author: Parag Kale\n\n\n\nAs previously announced, a supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis is under review by the U.S. Food and Drug Administration (FDA), with an action date of October 8, 2023 under the Prescription Drug User Fee Act (PDUFA). Patisiran is the established name for ONPATTRO®, which is approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.\n\n\nONPATTRO Indication and Important Safety Information Indication\n\n\nONPATTRO is indicated for...